title: Aspirin for primary prevention of atherothrombotic vascular events: how much "conclusive" is "conclusive?".
authors.forename: Francesco
authors.initials: F
authors.lastname: Brigo
authors.forename: Monica
authors.initials: M
authors.lastname: Storti
authors.forename: Piergiorgio
authors.initials: P
authors.lastname: Lochner
authors.forename: Frediano
authors.initials: F
authors.lastname: Tezzon
authors.forename: Raffaele
authors.initials: R
authors.lastname: Nardone
mesh_terms: D001241:Aspirin / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D058226:Plaque, Atherosclerotic / Q000150:complications* / Q000188:drug therapy; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D011322:Primary Prevention / Q000379:methods*; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*
chemical_list: D010975:Platelet Aggregation Inhibitors; D001241:Aspirin